Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot

Alzheimer's and Dementia

Volumn 8, Issue 4, 2012, Pages 312-336

  Hampel, Harald ^a   Lista, Simone ^a   Khachaturian, Zaven S ^b  

^a GOETHE UNIVERSITY   (Germany)

^b Campaign to Prevent Alzheimer's Disease by 2020 (PAD2020)   (United States)

Author keywords

Alzheimer's disease; Biomarker; CSF; Genetics; Mild cognitive impairment; Neuroimaging; Prodromal AD

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; BETA SECRETASE 1; BIOLOGICAL MARKER; CHROMOGRANIN A; FLUORODEOXYGLUCOSE F 18; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PITTSBURGH COMPOUND B; PROTEOME; TAU PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

AGING; ALZHEIMER DISEASE; APOPTOSIS; BINDING AFFINITY; BIOINFORMATICS; BLOOD BRAIN BARRIER; CELL CYCLE PROGRESSION; CEREBROSPINAL FLUID; COGNITION; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DNA SEQUENCE; ENDOPHENOTYPE; FOLLOW UP; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE DELETION; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENOTYPE; GRAY MATTER; HIGH THROUGHPUT SCREENING; HIGH THROUGHPUT SEQUENCING; HIPPOCAMPUS; HUMAN; LONG TERM POTENTIATION; MASS SPECTROMETRY; METABOLITE; MILD COGNITIVE IMPAIRMENT; NERVE CELL DEGENERATION; NERVE FIBER DEGENERATION; NEUROFIBRILLARY TANGLE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEOMICS; RELIABILITY; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYSTEMS BIOLOGY; THROMBOCYTE MEMBRANE; VALIDITY; WHITE MATTER;

EID: 84863224067     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2012.05.2116     Document Type: Note

References (162)

1. K. Broich, M. Weiergräber, and H. Hampel Biomarkers in clinical trials for neurodegenerative diseases: regulatory perspectives and requirements Prog Neurobiol 95 2011 498 500
2. B. Dubois, H.H. Feldman, C. Jacova, S.T. Dekosky, P. Barberger-Gateau, and J. Cummings Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria Lancet Neurol 6 2007 734 746 (Pubitemid 47058377)
3. B. Dubois, H.H. Feldman, C. Jacova, J.L. Cummings, S.T. Dekosky, and P. Barberger-Gateau Revising the definition of Alzheimer's disease: a new lexicon Lancet Neurol 9 2010 1118 1127
4. G. McKhann, D. Drachman, M. Folstein, R. Katzman, D. Price, and E.M. Stadlan Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease Neurology 34 1984 939 944 (Pubitemid 14076461)
5. G.M. McKhann, D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack Jr., and C.H. Kawas The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 263 269
6. R.A. Sperling, P.S. Aisen, L.A. Beckett, D.A. Bennett, S. Craft, and A.M. Fagan Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 280 292
7. M.S. Albert, S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, and N.C. Fox The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease Alzheimers Dement 7 2011 270 279
8. M. Garcia-Alloza, M. Subramanian, D. Thyssen, L.A. Borrelli, A. Fauq, and P. Das Existing plaques and neuritic abnormalities in APP: PS1 mice are not affected by administration of the gamma-secretase inhibitor LY-411575 Mol Neurodegener 4 2009 19
9. B. Vellas, P.S. Aisen, C. Sampaio, M. Carrillo, P. Scheltens, and B. Scherrer Prevention trials in Alzheimer's disease: an EU-US task force report Prog Neurobiol 95 2011 594 600
10. C. Noelker, H. Hampel, and R. Dodel Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases: current progress and clinical potential Mol Diagn Ther 15 2011 83 102
11. L. Thomas Labor und diagnose 2007 TH-Books Frankfurt am Main, Germany
12. E.R. Siemers How can we recognize "disease modification" effects? J Nutr Health Aging 13 2009 341 343
13. H. Hampel, R. Frank, K. Broich, S.J. Teipel, R.G. Katz, and J. Hardy Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives Nat Rev Drug Discov 9 2010 560 574
14. R. Frank, and R. Hargreaves Clinical biomarkers in drug discovery and development Nat Rev Drug Discov 2 2003 566 580 (Pubitemid 37361748)
15. Biomarker Definitions Working Group Biomarkers and surrogate endpoints: preferred definitions and conceptual framework Clin Pharmacol Ther 69 2001 89 95
16. P. Schneider, H. Hampel, and K. Buerger Biological marker candidates of Alzheimer's disease in blood, plasma, and serum CNS Neurosci Ther 15 2009 358 374
17. J.Q. Trojanowski, and H. Hampel Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and intervention Prog Neurobiol 95 2011 491 495
18. P. Nicotera, and H. Hampel Perspectives of worldwide translational biomarker research in neurodegenerative diseases Prog Neurobiol 95 2011 496 497
19. L. Bertram, and H. Hampel The role of genetics for biomarker development in neurodegeneration Prog Neurobiol 95 2011 501 504
20. H. Hampel, D. Prvulovic, S. Teipel, F. Jessen, C. Luckhaus, and L. Frölich The future of Alzheimer's disease: the next 10 years Prog Neurobiol 95 2011 718 728
21. K. Herrup Reimagining Alzheimer's disease-an age-based hypothesis J Neurosci 30 2010 16755 16762
22. N.F. Schor What the halted phase III γ-secretase inhibitor trial may (or may not) be telling us Ann Neurol 69 2011 237 239
23. C.R. Jack Jr. Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play Radiology 263 2012 344 361
24. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, and D.P. Holt Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 2004 306 319 (Pubitemid 38269583)
25. C.R. Jack Jr., D.S. Knopman, W.J. Jagust, L.M. Shaw, P.S. Aisen, and M.W. Weiner Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade Lancet Neurol 9 2010 119 128
26. T. Grimmer, S. Tholen, B.H. Yousefi, P. Alexopoulos, A. Förschler, and H. Förstl Progression of cerebral amyloid load is associated with the apolipoprotein E ε4 genotype in Alzheimer's disease Biol Psychiatry 68 2010 879 884
27. C.R. Jack Jr., V.J. Lowe, S.D. Weigand, H.J. Wiste, M.L. Senjem, and D.S. Knopman Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease Brain 132 2009 1355 1365
28. C.R. Jack Jr., V.J. Lowe, M.L. Senjem, S.D. Weigand, B.J. Kemp, and M.M. Shiung 11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment Brain 131 2008 665 680 (Pubitemid 351294719)
29. A.M. Fagan, M.A. Mintun, R.H. Mach, S.Y. Lee, C.S. Dence, and A.R. Shah Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans Ann Neurol 59 2006 512 519 (Pubitemid 43358072)
30. Hampel H. Amyloid-β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms. J Alzheimers Dis (in press).
31. R.L. Buckner, A.Z. Snyder, B.J. Shannon, G. LaRossa, R. Sachs, and A.F. Fotenos Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory J Neurosci 25 2005 7709 7717 (Pubitemid 41208641)
32. R.L. Buckner, J. Sepulcre, T. Talukdar, F.M. Krienen, H. Liu, and T. Hedden Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease J Neurosci 29 2009 1860 1873
33. A.D. Wagner, B.J. Shannon, I. Kahn, and R.L. Buckner Parietal lobe contributions to episodic memory retrieval Trends Cogn Sci 9 2005 445 453 (Pubitemid 41208254)
34. M.D. Greicius, G. Srivastava, A.L. Reiss, and V. Menon Default-mode network activity distinguishes Alzheimer's disease from healthy aging: evidence from functional MRI Proc Natl Acad Sci USA 101 2004 4637 4642 (Pubitemid 38437463)
35. C. Sorg, V. Riedl, M. Mühlau, V.D. Calhoun, T. Eichele, and L. Läer Selective changes of resting-state networks in individuals at risk for Alzheimer's disease Proc Natl Acad Sci USA 104 2007 18760 18765 (Pubitemid 350210770)
36. W. Koch, S. Teipel, S. Mueller, J. Benninghoff, M. Wagner, and A.L. Bokde Diagnostic power of default mode network resting state fMRI in the detection of Alzheimer's disease Neurobiol Aging 33 2012 466 478
37. A.L. Bokde, P. Lopez-Bayo, T. Meindl, S. Pechler, C. Born, and F. Faltraco Functional connectivity of the fusiform gyrus during a face-matching task in subjects with mild cognitive impairment Brain 129 2006 1113 1124
38. K. Herholz, E. Salmon, D. Perani, J.C. Baron, V. Holthoff, and L. Frölich Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET Neuroimage 17 2002 302 316
39. D.S. Karow, L.K. McEvoy, C. Fennema-Notestine, D.J. Hagler Jr., R.G. Jennings, and J.B. Brewer Relative capability of MR imaging and FDG PET to depict changes associated with prodromal and early Alzheimer disease Radiology 256 2010 932 942
40. P.M. Thompson, K.M. Hayashi, G. de Zubicaray, A.L. Janke, S.E. Rose, and J. Semple Dynamics of gray matter loss in Alzheimer's disease J Neurosci 23 2003 994 1005 (Pubitemid 36206191)
41. Jack CR Jr, Vemuri P, Wiste HJ, Weigand SD, Lesnick TG, Lowe V, et al. Shapes of the trajectories of 5 major biomarkers of Alzheimer disease. Arch Neurol (in press).
42. M. Ewers, R.A. Sperling, W.E. Klunk, M.W. Weiner, and H. Hampel Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia Trends Neurosci 34 2011 430 442
43. R.A. Sperling, P.S. Laviolette, K. O'Keefe, J. O'Brien, D.M. Rentz, and M. Pihlajamaki Amyloid deposition is associated with impaired default network function in older persons without dementia Neuron 63 2009 178 188
44. D.S. Knopman, C.R. Jack Jr., H.J. Wiste, S.D. Weigand, P. Vemuri, and V. Lowe Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease Neurology 78 2012 1576 1582
45. L. Mosconi, A. Pupi, and M.J. De Leon Brain glucose hypometabolism and oxidative stress in preclinical Alzheimer's disease Ann NY Acad Sci 1147 2008 180 195
46. L. Mosconi, D. Perani, S. Sorbi, K. Herholz, B. Nacmias, and V. Holthoff MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET Neurology 63 2004 2332 2340 (Pubitemid 40024346)
47. J. Koivunen, N. Scheinin, J.R. Virta, S. Aalto, T. Vahlberg, and K. Någren Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study Neurology 76 2011 1085 1090
48. A. Okello, J. Koivunen, P. Edison, H.A. Archer, F.E. Turkheimer, and K. Någren Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study Neurology 73 2009 754 760
49. J.R. Petrella, F.C. Sheldon, S.E. Prince, V.D. Calhoun, and P.M. Doraiswamy Default mode network connectivity in stable vs progressive mild cognitive impairment Neurology 76 2011 511 517
50. S.L. Miller, E. Fenstermacher, J. Bates, D. Blacker, R.A. Sperling, and B.C. Dickerson Hippocampal activation in adults with mild cognitive impairment predicts subsequent cognitive decline J Neurol Neurosurg Psychiatry 79 2008 630 635 (Pubitemid 351829432)
51. D. Prvulovic, and H. Hampel Ethical considerations of biomarker use in neurodegenerative diseases-a case study of Alzheimer's disease Prog Neurobiol 95 2011 517 519
52. B. Vellas, H. Hampel, M.E. Rougé-Bugat, M. Grundman, S. Andrieu, and S. Abu-Shakra Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology J Nutr Health Aging 16 2012 339 345
53. H. Hampel, and D. Prvulovic Are biomarkers harmful to recruitment and retention in Alzheimer's disease clinical trials? An international perspective J Nutr Health Aging 16 2012 346 348
54. K. Blennow, H. Hampel, M. Weiner, and H. Zetterberg Cerebrospinal fluid and plasma biomarkers in Alzheimer disease Nat Rev Neurol 6 2010 131 144
55. H. Hampel, K. Bürger, S.J. Teipel, A.L. Bokde, H. Zetterberg, and K. Blennow Core candidate neurochemical and imaging biomarkers of Alzheimer's disease Alzheimers Dement 4 2008 38 48
56. K. Buerger, M. Ewers, T. Pirttilä, R. Zinkowski, I. Alafuzoff, and S.J. Teipel CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease Brain 129 2006 3035 3041 (Pubitemid 44684523)
57. H. Hampel, K. Bürger, J.C. Pruessner, R. Zinkowski, J. DeBernardis, and D. Kerkman Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease Arch Neurol 62 2005 770 773 (Pubitemid 40656092)
58. C. Hesse, L. Rosengren, N. Andreasen, P. Davidsson, H. Vanderstichele, and E. Vanmechelen Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke Neurosci Lett 297 2001 187 190 (Pubitemid 32011305)
59. M. Riemenschneider, S. Wagenpfeil, H. Vanderstichele, M. Otto, J. Wiltfang, and H. Kretzschmar Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias Mol Psychiatry 8 2003 343 347 (Pubitemid 36712928)
60. H. Hampel, K. Buerger, R. Zinkowski, S.J. Teipel, A. Goernitz, and N. Andreasen Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study Arch Gen Psychiatry 61 2004 95 102 (Pubitemid 38044645)
61. H. Hampel, K. Blennow, L.M. Shaw, Y.C. Hoessler, H. Zetterberg, and J.Q. Trojanowski Total and phosphorylated tau protein as biological markers of Alzheimer's disease Exp Gerontol 45 2010 30 40
62. H. Hampel, Y. Shen, D.M. Walsh, P. Aisen, L.M. Shaw, and H. Zetterberg Biological markers of amyloid beta-related mechanisms in Alzheimer's disease Exp Neurol 223 2010 334 346
63. K. Blennow Cerebrospinal fluid protein biomarkers for Alzheimer's disease NeuroRx 1 2004 213 225 (Pubitemid 46589353)
64. K. Blennow, and H. Hampel CSF markers for incipient Alzheimer's disease Lancet Neurol 2 2003 605 613 (Pubitemid 37162569)
65. N. Mattsson, H. Zetterberg, O. Hansson, N. Andreasen, L. Parnetti, and M. Jonsson CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment JAMA 302 2009 385 393
66. M.W. Weiner, D.P. Veitch, P.S. Aisen, L.A. Beckett, N.J. Cairns, and R.C. Green The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception Alzheimers Dement 8 2012 S1 S68
67. P. Buchhave, L. Minthon, H. Zetterberg, A.K. Wallin, K. Blennow, and O. Hansson Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia Arch Gen Psychiatry 69 2012 98 106
68. C.R. Jack Jr., P. Vemuri, H.J. Wiste, S.D. Weigand, P.S. Aisen, and J.Q. Trojanowski Evidence for ordering of Alzheimer disease biomarkers Arch Neurol 68 2011 1526 1535
69. A. Olsson, K. Höglund, M. Sjögren, N. Andreasen, L. Minthon, and L. Lannfelt Measurement of alpha- and beta-secretase cleaved amyloid precursor protein in cerebrospinal fluid from Alzheimer patients Exp Neurol 183 2003 74 80 (Pubitemid 37075858)
70. H. Zetterberg, U. Andreasson, O. Hansson, G. Wu, S. Sankaranarayanan, and M.E. Andersson Elevated cerebrospinal fluid BACE1 activity in incipient Alzheimer disease Arch Neurol 65 2008 1102 1107
71. P. Lewczuk, H. Kamrowski-Kruck, O. Peters, I. Heuser, F. Jessen, and J. Popp Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study Mol Psychiatry 15 2010 138 145
72. Blennow K, Zetterberg H, Fagan AM. Fluid Biomarkers in Alzheimer disease. Cold Spring Harb Perspect Med (in press).
73. R.M. Holsinger, C.A. McLean, S.J. Collins, C.L. Masters, and G. Evin Increased beta-secretase activity in cerebrospinal fluid of Alzheimer's disease subjects Ann Neurol 55 2004 898 899 (Pubitemid 38702591)
74. R.M. Holsinger, J.S. Lee, A. Boyd, C.L. Masters, and S.J. Collins CSF BACE1 activity is increased in CJD and Alzheimer disease versus [corrected] other dementias Neurology 67 2006 710 712 (Pubitemid 44273629)
75. J.H. Verheijen, L.G. Huisman, N. van Lent, U. Neumann, P. Paganetti, and C.E. Hack Detection of a soluble form of BACE-1 in human cerebrospinal fluid by a sensitive activity assay Clin Chem 52 2006 1168 1174 (Pubitemid 43794431)
76. Z. Zhong, M. Ewers, S. Teipel, K. Bürger, A. Wallin, and K. Blennow Levels of beta-secretase (BACE1) in cerebrospinal fluid as a predictor of risk in mild cognitive impairment Arch Gen Psychiatry 64 2007 718 726 (Pubitemid 46878672)
77. H. Hampel, and Y. Shen Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) as a biological candidate marker of Alzheimer's disease Scand J Clin Lab Invest 69 2009 8 12
78. M. Ewers, Z. Zhong, K. Bürger, A. Wallin, K. Blennow, and S.J. Teipel Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease Brain 131 2008 1252 1258
79. D.M. Walsh, and D.J. Selkoe Aβ oligomers - a decade of discovery J Neurochem 101 2007 1172 1184
80. L.W. Hung, G.D. Ciccotosto, E. Giannakis, D.J. Tew, K. Perez, and C.L. Masters Amyloid-beta peptide (Abeta) neurotoxicity is modulated by the rate of peptide aggregation: abeta dimers and trimers correlate with neurotoxicity J Neurosci 28 2008 11950 11958
81. A.N. Santos, M. Ewers, L. Minthon, A. Simm, R.E. Silber, and K. Blennow Amyloid-β oligomers in cerebrospinal fluid are associated with cognitive decline in patients with Alzheimer's disease J Alzheimers Dis 29 2012 171 176
82. Masters CL, Selkoe DJ. Biochemistry of amyloid β-protein and amyloid deposits in Alzheimer disease. Cold Spring Harb Perspect Med (in press).
83. K. Blennow Biomarkers in Alzheimer's disease drug development Nat Med 16 2010 1218 1222
84. Y. Shen, P. He, Z. Zhong, C. McAllister, and K. Lindholm Distinct destructive signal pathways of neuronal death in Alzheimer's disease Trends Mol Med 12 2006 574 579 (Pubitemid 44780197)
85. R. Li, L. Yang, K. Lindholm, Y. Konishi, X. Yue, and H. Hampel Tumor necrosis factor death receptor signaling cascade is required for amyloid-beta protein-induced neuron death J Neurosci 24 2004 1760 1771 (Pubitemid 38240974)
86. P. He, Z. Zhong, K. Lindholm, L. Berning, W. Lee, and C. Lemere Deletion of tumor necrosis factor death receptor inhibits amyloid beta generation and prevents learning and memory deficits in Alzheimer's mice J Cell Biol 178 2007 829 841 (Pubitemid 47347367)
87. X. Cheng, L. Yang, P. He, R. Li, and Y. Shen Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients J Alzheimers Dis 19 2010 621 630
88. H. Jiang, H. Hampel, D. Prvulovic, A. Wallin, K. Blennow, and R. Li Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease Mol Neurodegener 6 2011 69
89. H. Hampel, S.J. Teipel, F. Padberg, A. Haslinger, M. Riemenschneider, and M.J. Schwarz Discriminant power of combined cerebrospinal fluid tau protein and of the soluble interleukin-6 receptor complex in the diagnosis of Alzheimer's disease Brain Res 823 1999 104 112 (Pubitemid 29225499)
90. H. Hampel, T. Sunderland, H.U. Kötter, C. Schneider, S.J. Teipel, and F. Padberg Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease Brain Res 780 1998 356 359 (Pubitemid 28082925)
91. R.J. Perrin, R. Craig-Schapiro, J.P. Malone, A.R. Shah, P. Gilmore, and A.E. Davis Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease PLoS One 6 2011 e16032
92. R. Craig-Schapiro, M. Kuhn, C. Xiong, E.H. Pickering, J. Liu, and T.P. Misko Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis PLoS One 6 2011 e18850
93. R. Tarawneh, G. D'Angelo, E. Macy, C. Xiong, D. Carter, and N.J. Cairns Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease Ann Neurol 70 2011 274 285
94. R. Tarawneh, J.M. Lee, J.H. Ladenson, J.C. Morris, and D.M. Holtzman CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease Neurology 78 2012 709 719
95. H. Hampel, A. Mitchell, K. Blennow, R.A. Frank, S. Brettschneider, and L. Weller Core biological marker candidates of Alzheimer's disease - perspectives for diagnosis, prediction of outcome and reflection of biological activity J Neural Transm 111 2004 247 272 (Pubitemid 38316604)
96. B.D. Zipser, C.E. Johanson, L. Gonzalez, T.M. Berzin, R. Tavares, and C.M. Hulette Microvascular injury and blood-brain barrier leakage in Alzheimer's disease Neurobiol Aging 28 2007 977 986 (Pubitemid 46635913)
97. K.A. Bates, G. Verdile, Q.X. Li, D. Ames, P. Hudson, and C.L. Masters Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests Mol Psychiatry 14 2009 469 486
98. M.C. Irizarry Biomarkers of Alzheimer disease in plasma NeuroRx 1 2004 226 234 (Pubitemid 46591884)
99. P.D. Mehta, T. Pirttilä, S.P. Mehta, E.A. Sersen, P.S. Aisen, and H.M. Wisniewski Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease Arch Neurol 57 2000 100 105 (Pubitemid 30027637)
100. A. Sagare, R. Deane, R.D. Bell, B. Johnson, K. Hamm, and R. Pendu Clearance of amyloid-beta by circulating lipoprotein receptors Nat Med 13 2007 1029 1031 (Pubitemid 47517512)
101. K.A. Bruggink, M. Müller, H.B. Kuiperij, and M.M. Verbeek Methods for analysis of amyloid-β aggregates J Alzheimers Dis 28 2012 735 758
102. W. Xia, T. Yang, G. Shankar, I.M. Smith, Y. Shen, and D.M. Walsh A specific enzyme-linked immunosorbent assay for measuring beta-amyloid protein oligomers in human plasma and brain tissue of patients with Alzheimer disease Arch Neurol 66 2009 190 199
103. A. Padovani, L. Pastorino, B. Borroni, F. Colciaghi, L. Rozzini, and R. Monastero Amyloid precursor protein in platelets: a peripheral marker for the diagnosis of sporadic AD Neurology 57 2001 2243 2248 (Pubitemid 34016458)
104. A. Padovani, B. Borroni, F. Colciaghi, C. Pettenati, E. Cottini, and C. Agosti Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease Arch Neurol 59 2002 71 75 (Pubitemid 34052558)
105. D.A. Butterfield, A. Castegna, C.M. Lauderback, and J. Drake Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death Neurobiol Aging 23 2002 655 664 (Pubitemid 35217687)
106. D. Praticò, C.M. Clark, F. Liun, J. Rokach, V.Y. Lee, and J.Q. Trojanowski Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease Arch Neurol 59 2002 972 976 (Pubitemid 34640757)
107. T.J. Montine, J.F. Quinn, D. Milatovic, L.C. Silbert, T. Dang, and S. Sanchez Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease Ann Neurol 52 2002 175 179 (Pubitemid 34810597)
108. H.L. Weiner, and D.J. Selkoe Inflammation and therapeutic vaccination in CNS diseases Nature 420 2002 879 884 (Pubitemid 36019642)
109. S.E. O'Bryant, G. Xiao, R. Barber, J. Reisch, R. Doody, and T. Fairchild A serum protein-based algorithm for the detection of Alzheimer disease Arch Neurol 67 2010 1077 1081
110. M.J. Engelhart, M.I. Geerlings, J. Meijer, A. Kiliaan, A. Ruitenberg, and J.C. van Swieten Inflammatory proteins in plasma and the risk of dementia: the rotterdam study Arch Neurol 61 2004 668 672 (Pubitemid 38637682)
111. H. Hampel, M. Scheloske, and A. Haslinger The interleukin-6 receptor complex J. Rogers, Neuroinflammatory Mechanisms in Alzheimer's Disease: Basic and Clinical Research 2001 Birkhauser Publishers Basel 121 143
112. H. Hampel, A. Haslinger, M. Scheloske, F. Padberg, P. Fischer, and J. Unger Pattern of interleukin-6 receptor complex immunoreactivity between cortical regions of rapid autopsy normal and Alzheimer's disease brain Eur Arch Psychiatry Clin Neurosci 255 2005 269 278 (Pubitemid 41187036)
113. H. Hampel, D. Schoen, M.J. Schwarz, H.U. Kötter, C. Schneider, and T. Sunderland Interleukin-6 is not altered in cerebrospinal fluid of first-degree relatives and patients with Alzheimer's disease Neurosci Lett 228 1997 143 146 (Pubitemid 27272153)
114. H. Hampel, T. Sunderland, H.U. Kötter, C. Schneider, S.J. Teipel, and F. Padberg Decreased soluble interleukin-6 receptor in cerebrospinal fluid of patients with Alzheimer's disease Brain Res 780 1998 356 359 (Pubitemid 28082925)
115. M. Bagli, A. Papassotiropoulos, H. Hampel, K. Becker, F. Jessen, and K. Bürger Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Results of a pilot study Eur Arch Psychiatry Clin Neurosci 253 2003 44 48 (Pubitemid 37205225)
116. K. Buerger, A. Ernst, M. Ewers, O. Uspenskaya, M. Omerovic, and N.G. Morgenthaler Blood-based microcirculation markers in Alzheimer's disease-diagnostic value of midregional pro-atrial natriuretic peptide/C-terminal endothelin-1 precursor fragment ratio Biol Psychiatry 65 2009 979 984
117. S. Ray, M. Britschgi, C. Herbert, Y. Takeda-Uchimura, A. Boxer, and K. Blennow Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins Nat Med 13 2007 1359 1362 (Pubitemid 350073592)
118. M. Britschgi, and T. Wyss-Coray Blood protein signature for the early diagnosis of Alzheimer disease Arch Neurol 66 2009 161 165
119. A. Hye, S. Lynham, M. Thambisetty, M. Causevic, J. Campbell, and H.L. Byers Proteome-based plasma biomarkers for Alzheimer's disease Brain 129 2006 3042 3050 (Pubitemid 44684524)
120. M. Thambisetty, A. Simmons, A. Hye, J. Campbell, E. Westman, and Y. Zhang Plasma biomarkers of brain atrophy in Alzheimer's disease PLoS One 6 2011 e28527
121. S. Lovestone, A. Güntert, A. Hye, S. Lynham, M. Thambisetty, and M. Ward Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers Expert Rev Proteomics 4 2007 227 238 (Pubitemid 46588458)
122. C. Czech, P. Berndt, K. Busch, O. Schmitz, J. Wiemer, and V. Most Metabolite profiling of Alzheimer's disease cerebrospinal fluid PLoS One 7 2012 e31501
123. H. Kitano Systems biology: a brief overview Science 295 2001 1662 1664 (Pubitemid 34202893)
124. F. Noorbakhsh, C.M. Overall, and C. Power Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology Trends Neurosci 32 2009 88 100
125. A. Pandey, and M. Mann Proteomics to study genes and genomes Nature 405 2000 837 846 (Pubitemid 30407862)
126. M. Tyers, and M. Mann From genomics to proteomics Nature 422 2003 193 197 (Pubitemid 36362756)
127. J.A. Miller, M.C. Oldham, and D.H. Geschwind A systems level analysis of transcriptional changes in Alzheimer's disease and normal aging J Neurosci 28 2008 1410 1420 (Pubitemid 351231536)
128. A. Aitken 14-3-3 proteins: a historic overview Semin Cancer Biol 16 2006 162 172 (Pubitemid 43796128)
129. D. Harold, R. Abraham, P. Hollingworth, R. Sims, A. Gerrish, and M.L. Hamshere Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease Nat Genet 41 2009 1088 1093
130. J.C. Lambert, S. Heath, G. Even, D. Campion, K. Sleegers, and M. Hiltunen Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease Nat Genet 41 2009 1094 1099
131. S. Seshadri, A.L. Fitzpatrick, M.A. Ikram, A.L. DeStefano, V. Gudnason, and M. Boada Genome-wide analysis of genetic loci associated with Alzheimer disease JAMA 303 2010 1832 1840
132. P. Hollingworth, D. Harold, R. Sims, A. Gerrish, J.C. Lambert, and M.M. Carrasquillo Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease Nat Genet 43 2011 429 435
133. A.C. Naj, G. Jun, G.W. Beecham, L.S. Wang, B.N. Vardarajan, and J. Buros Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease Nat Genet 43 2011 436 441
134. W.J. Ansorge Next-generation DNA sequencing techniques N Biotechnol 25 2009 195 203
135. E. Check-Hayden International genome project launched Nature 541 2008 378 379
136. J. Kaiser A plan to capture human diversity in 1000 genomes Science 319 2008 395 (Pubitemid 351160548)
137. I. Gottesman, and J. Shields Schizophrenia and genetics: a twin study vantage point 1972 Academic Press New York
138. S.G. Mueller, M.W. Weiner, L.J. Thal, R.C. Petersen, C.R. Jack, and W. Jagust Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI) Alzheimers Dement 1 2005 55 66 (Pubitemid 43348857)
139. S. Kim, S. Swaminathan, L. Shen, S.L. Risacher, K. Nho, and T. Foroud Genome-wide association study of CSF biomarkers Abeta1-42, t-tau, and p-tau181p in the ADNI cohort Neurology 76 2011 69 79
140. L. Bertram, M.B. McQueen, K. Mullin, D. Blacker, and R.E. Tanzi Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database Nat Genet 39 2007 17 23 (Pubitemid 46026496)
141. R. Cacabelos Pharmacogenomics and therapeutic prospects in dementia Eur Arch Psychiatry Clin Neurosci 258 2008 28 47 (Pubitemid 351424036)
142. R. Cacabelos Pharmacogenomics and therapeutic strategies for dementia Expert Rev Mol Diagn 9 2009 567 611
143. T. Zetzsche, D. Rujescu, J. Hardy, and H. Hampel Advances and perspectives from genetic research: development of biological markers in Alzheimer's disease Expert Rev Mol Diagn 10 2010 667 690
144. H. Hampel, G. Wilcock, S. Andrieu, P. Aisen, K. Blennow, and K. Broich Biomarkers for Alzheimer's disease therapeutic trials Prog Neurobiol 95 2011 579 593
145. S.F. Kingsmore Multiplexed protein measurement: technologies and applications of protein and antibody arrays Nat Rev Drug Discov 5 2006 310 320
146. N. Rifai, M.A. Gillette, and S.A. Carr Protein biomarker discovery and validation: the long and uncertain path to clinical utility Nat Biotechnol 24 2006 971 983 (Pubitemid 44215392)
147. K.G. Oliver, J.R. Kettman, and R.J. Fulton Multiplexed analysis of human cytokines by use of the FlowMetrix system Clin Chem 44 1998 2057 2060 (Pubitemid 28405791)
148. M.Y. Liu, A.M. Xydakis, R.C. Hoogeveen, P.H. Jones, E.O. Smith, and K.W. Nelson Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system Clin Chem 51 2005 1102 1109 (Pubitemid 43079385)
149. F. Vitzthum, F. Behrens, N.L. Anderson, and J.H. Shaw Proteomics: from basic research to diagnostic application: a review of requirements and needs J Proteome Res 4 2005 1086 1097 (Pubitemid 41208666)
150. R.W. Jones Dimebon disappointment Alzheimers Res Ther 2 2010 25
151. J. Cummings What can be inferred from the interruption of the semagacestat trial for treatment of Alzheimer's disease? Biol Psychiatry 68 2010 876 878
152. B. Vellas Tarenflurbil for Alzheimer's disease: a "shot on goal" that missed Lancet Neurol 9 2010 235 237
153. M.E. Csete, and J.C. Doyle Reverse engineering of biological complexity Science 295 2002 1664 1669 (Pubitemid 34202894)
154. J.F. Rual, K. Venkatesan, T. Hao, T. Hirozane-Kishikawa, A. Dricot, and N. Li Towards a proteome-scale map of the human protein-protein interaction network Nature 437 2005 1173 1178 (Pubitemid 41509356)
155. R. Tacutu, A. Budovsky, H. Yanai, and V.E. Fraifeld Molecular links between cellular senescence, longevity and age-related diseases - a systems biology perspective Aging (Albany, NY) 3 2011 1178 1191
156. P. Villoslada, L. Steinman, and S.E. Baranzini Systems biology and its application to the understanding of neurological diseases Ann Neurol 65 2009 124 139
157. H. Li, J. Xuan, Y. Wang, and M. Zhan Inferring regulatory networks Front Biosci 13 2008 263 275 (Pubitemid 351606128)
158. M. Hashimoto, N. Bogdanovic, I. Volkmann, M. Aoki, B. Winblad, and L.O. Tjernberg Analysis of microdissected human neurons by a sensitive ELISA reveals a correlation between elevated intracellular concentrations of Abeta42 and Alzheimer's disease neuropathology Acta Neuropathol 119 2010 543 554
159. R.J. Mishur, and S.L. Rea Applications of mass spectrometry to metabolomics and metabonomics: detection of biomarkers of aging and of age-related diseases Mass Spectrom Rev 31 2012 70 95
160. L.M. Shaw, H. Vanderstichele, M. Knapik-Czajka, M. Figurski, E. Coart, and K. Blennow Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI Acta Neuropathol 121 2011 597 609
161. Kesselheim AS, Karlawish J. Biomarkers unbound - the Supreme Court's ruling on diagnostic-test patents [published online ahead of print May 23, 2012]. N Engl J doi: 10.1056/NEJMp1204164.
162. Hampel H, Trokanowski JQ eds. Special Issue. Biological markers for neurodegenerative diseases. Prog Neurobiol 2011;95:491-728.